EA200200248A1 - Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств - Google Patents

Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств

Info

Publication number
EA200200248A1
EA200200248A1 EA200200248A EA200200248A EA200200248A1 EA 200200248 A1 EA200200248 A1 EA 200200248A1 EA 200200248 A EA200200248 A EA 200200248A EA 200200248 A EA200200248 A EA 200200248A EA 200200248 A1 EA200200248 A1 EA 200200248A1
Authority
EA
Eurasian Patent Office
Prior art keywords
branched
alkyl
aminopyrazol
funds
linear
Prior art date
Application number
EA200200248A
Other languages
English (en)
Other versions
EA005373B1 (ru
Inventor
Паоло Певарелло
Паоло Орсини
Габриэлла Тракуанди
Марио Варази
Эдвард Л. Фритцен
Марта А. Варпехоски
Бетси С. Пирс
Мария Габриэлла Браска
Original Assignee
Фармация Италия С.П.А.
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Италия С.П.А., Фармация Энд Апджон Компани filed Critical Фармация Италия С.П.А.
Publication of EA200200248A1 publication Critical patent/EA200200248A1/ru
Publication of EA005373B1 publication Critical patent/EA005373B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединения, являющиеся производными 3-аминопиразола, представленные формулой (I), где R представляет собой С-С-циклоалкильную группу, необязательно замещенную линейной или разветвленной C-C-алкильной или арилалкильной группой; Rпредставляет собой линейную или разветвленную C-С-алкильную, С-С-алкенильную, циклоалкильную, циклоалкенильную, гетероциклическую, арильную, арилалкильную, арилкарбонильную, арилоксиалкильную или арилалкенильную группу, каждая из которых необязательно может быть далее замещенной, как отмечено в описании; или их фармацевтически приемлемые соли. Соединения могут использоваться для лечения злокачественных опухолей, нарушений клеточной пролиферации, болезни Альцгеймера, вирусных инфекций, аутоиммунных заболеваний или нейродегенеративных заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200248A 1999-08-12 2000-05-05 Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств EA005373B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37283199A 1999-08-12 1999-08-12
PCT/US2000/006699 WO2001012189A1 (en) 1999-08-12 2000-05-05 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents

Publications (2)

Publication Number Publication Date
EA200200248A1 true EA200200248A1 (ru) 2002-08-29
EA005373B1 EA005373B1 (ru) 2005-02-24

Family

ID=23469802

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200248A EA005373B1 (ru) 1999-08-12 2000-05-05 Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств

Country Status (35)

Country Link
US (2) US7034049B1 (ru)
EP (1) EP1202733B1 (ru)
JP (1) JP2003507329A (ru)
KR (1) KR20020060160A (ru)
CN (1) CN1373662A (ru)
AP (1) AP2002002442A0 (ru)
AR (1) AR026122A1 (ru)
AT (1) ATE305782T1 (ru)
AU (1) AU4971400A (ru)
BG (1) BG106480A (ru)
BR (1) BR0013143A (ru)
CA (1) CA2383555C (ru)
CZ (1) CZ2002422A3 (ru)
DE (1) DE60023012T2 (ru)
DK (1) DK1202733T3 (ru)
EA (1) EA005373B1 (ru)
EE (1) EE200200065A (ru)
ES (1) ES2249270T3 (ru)
GE (1) GEP20053476B (ru)
HK (1) HK1046866A1 (ru)
HR (1) HRP20020128A2 (ru)
HU (1) HUP0203542A3 (ru)
IL (1) IL147923A0 (ru)
IS (1) IS6265A (ru)
MA (1) MA25493A1 (ru)
MX (1) MXPA02001498A (ru)
NO (1) NO20020684L (ru)
NZ (1) NZ517237A (ru)
OA (1) OA12046A (ru)
PE (1) PE20010130A1 (ru)
PL (1) PL353455A1 (ru)
SK (1) SK1812002A3 (ru)
WO (1) WO2001012189A1 (ru)
YU (1) YU9602A (ru)
ZA (1) ZA200201511B (ru)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9901691D0 (en) 1999-01-26 1999-03-17 Cerebrus Ltd Chemical compounds
ATE305782T1 (de) * 1999-08-12 2005-10-15 Pharmacia Italia Spa 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
CA2399274A1 (en) 2000-02-07 2001-08-09 Mark E. Salvati 3-aminopyrazole inhibitors of cyclin dependent kinases
ES2236217T3 (es) 2000-04-25 2005-07-16 Bristol-Myers Squibb Company Uso de 5.tio.,sulfinil- y sulfonilpirazolo 3,4-b)-piridinas como inhibidores de la quinasa dependiente de la ciclina.
DE10037310A1 (de) * 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
YU14703A (sh) * 2000-08-31 2006-05-25 Pfizer Products Inc. Derivati pirazola i njihova upotreba kao inhibitora protein kinaze
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
WO2002070515A2 (en) * 2001-01-26 2002-09-12 Pharmacia Italia Spa Chromane derivatives, process for their preparation and their use as antitumor agents
JP2004526721A (ja) * 2001-03-02 2004-09-02 エフ．ホフマン−ラ　ロシュ　アーゲー Ｉｐアンタゴニストとしてのアルコキシカルボニルアミノヘテロアリールカルボン酸誘導体
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
ATE445400T1 (de) 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148617A1 (de) * 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
US7087768B2 (en) * 2001-09-27 2006-08-08 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
US7514406B2 (en) * 2001-11-27 2009-04-07 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6593477B1 (en) 2002-10-29 2003-07-15 Eastman Kodak Company Synthesis of 3-acylaminopyrazoles
AU2003291885A1 (en) * 2002-12-10 2004-06-30 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
UA81790C2 (ru) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Замещенные пиролопиразольные производные как ингибиторы киназы
WO2004063194A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
EP1610776A4 (en) * 2003-03-27 2007-03-28 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
CA2526578C (en) 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
JP4220548B2 (ja) 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド アシル化されたアミノ酸・アミジルピラゾール、および関連化合物
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
WO2005073198A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CN1938279B (zh) 2004-01-30 2011-09-14 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白调控剂
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
EP1824835A1 (en) * 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatic glucokinase activators
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7361672B2 (en) 2004-12-23 2008-04-22 Hoffmann-La Roche Inc. Heteroarylacetamide inhibitors of factor Xa
FR2880540B1 (fr) * 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
CA2613303C (en) * 2005-07-11 2012-06-19 Mitsubishi Tanabe Pharma Corporation An oxime derivative for use as a glucokinase activator
WO2007009898A1 (en) 2005-07-19 2007-01-25 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
KR20080090381A (ko) * 2005-08-29 2008-10-08 제라드 엠. 하우지 테라뮤틴 조절물질
UY30048A1 (es) 2005-12-23 2007-07-31 Astrazeneca Ab Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
WO2007081966A2 (en) * 2006-01-09 2007-07-19 University Of Southern California Small molecules for treating cancer and abnormal cell proliferation disorders
WO2007095383A2 (en) * 2006-02-15 2007-08-23 Myriad Genetics, Inc. Prodrugs
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US8211925B2 (en) 2006-04-28 2012-07-03 Transtech Pharma, Inc. Benzamide glucokinase activators
EP2016068A1 (en) * 2006-05-03 2009-01-21 AstraZeneca AB Pyrazole derivatives and their use as pi3k inhibitors
EP2049106A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008084873A1 (ja) * 2007-01-10 2008-07-17 Mitsubishi Tanabe Pharma Corporation オキシム誘導体
EP2105435A4 (en) * 2007-01-10 2011-06-15 Mitsubishi Tanabe Pharma Corp Hydrazone derivatives
EP2125735B1 (en) 2007-02-28 2012-06-27 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
KR100923540B1 (ko) * 2007-11-23 2009-10-27 한국과학기술연구원 5-아실하이드라진카르보닐-3,4-디치환 피라졸 유도체 및이의 제조방법
JP2011524888A (ja) * 2008-06-19 2011-09-08 アストラゼネカ アクチボラグ ピラゾール化合物４３６
JP5650529B2 (ja) * 2008-07-10 2015-01-07 一般社団法人ファルマバレープロジェクト支援機構 キノリンカルボキサミド誘導体を有効成分とするｓｔａｔ３阻害剤
US20110129467A1 (en) 2008-07-24 2011-06-02 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
CA2744711C (en) * 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
AR075153A1 (es) * 2009-01-30 2011-03-16 Glaxosmithkline Llc Compuesto hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil)-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2- tiofenocarboxamida en forma cristalina, composicion farmaceitica que lo comprende, procedimiento para prepararla, su uso para preparar un medicamento util para tratar o disminuir la
WO2010129681A1 (en) * 2009-05-05 2010-11-11 Van Andel Research Institute Methods for treating autophagy-related disorders
EP2467137A1 (en) * 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
EP2947073B1 (en) * 2009-10-22 2019-04-03 Fibrotech Therapeutics Pty Ltd Fused ring analogues of anti-fibrotic agents
CN102711749A (zh) * 2009-11-05 2012-10-03 莱西肯医药有限公司 用于癌症治疗的色氨酸羟化酶抑制剂
NZ718622A (en) * 2010-03-30 2018-03-23 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN103108868B (zh) 2010-06-07 2015-11-25 诺沃梅迪科斯有限公司 呋喃基化合物及其用途
WO2011158108A2 (en) 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
AU2011323617B2 (en) * 2010-11-03 2015-02-05 Corteva Agriscience Llc Pesticidal compositions and processes related thereto
US9073895B2 (en) * 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
BR112013008527A2 (pt) 2010-12-17 2016-07-12 Nerviano Medical Sciences Srl derivados de pirazolo-quinazolina substituídos como inibidores de cinase
US20140249105A1 (en) * 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
EP2755652B1 (en) * 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
CA2852688C (en) 2011-10-26 2021-06-29 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
RU2623233C2 (ru) 2012-04-27 2017-06-23 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и относящиеся к ним способы
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN103936637B (zh) * 2013-01-18 2016-04-06 北京大学 E-3,4-二羟苯乙烯基亚砜类化合物的制备方法及其作为神经保护药物的应用
EA029296B1 (ru) 2013-03-15 2018-03-30 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Пиридиновые производные в качестве ингибиторов реаранжированной в процессе трансфекции (ret) киназы
SG10201707486XA (en) 2013-03-15 2017-10-30 Verseon Corp Halogenopyrazoles as inhibitors of thrombin
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
EP2968297B1 (en) 2013-03-15 2018-09-26 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
WO2014170350A1 (en) * 2013-04-17 2014-10-23 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
CN103265535B (zh) * 2013-05-14 2015-06-17 浙江医药高等专科学校 抗肿瘤化合物、其制备方法和用途
EP3039021A1 (en) 2013-08-30 2016-07-06 Ambit Biosciences Corporation Biaryl acetamide compounds and methods of use thereof
MX2016004940A (es) 2013-10-17 2016-06-28 Dow Agrosciences Llc Proceso para la preparacion de compuestos plaguicidas.
KR20160074542A (ko) 2013-10-17 2016-06-28 다우 아그로사이언시즈 엘엘씨 살충성 화합물의 제조 방법
WO2015058028A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CA2925873A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2015058022A1 (en) 2013-10-17 2015-04-23 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
CN105636445B (zh) 2013-10-17 2018-12-07 美国陶氏益农公司 制备杀虫化合物的方法
CN105636443A (zh) 2013-10-17 2016-06-01 美国陶氏益农公司 制备杀虫化合物的方法
US9497966B2 (en) 2013-10-22 2016-11-22 Dow Agrosciences Llc Pesticidal compositions and related methods
KR20160074635A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
CA2926431A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
MX2016005326A (es) 2013-10-22 2016-08-08 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
CN105828608A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 杀虫组合物和与其相关的方法
JP2016536307A (ja) 2013-10-22 2016-11-24 ダウ アグロサイエンシィズ エルエルシー 農薬組成物および関連する方法
WO2015061170A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
RU2016119368A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергетические пестицидные композиции и связанные с ними способы
KR20160074632A (ko) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 상승작용적 살충 조성물 및 관련 방법
CN105828613A (zh) 2013-10-22 2016-08-03 美国陶氏益农公司 协同杀虫组合物和与其相关的方法
WO2015061171A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
MX2016005327A (es) 2013-10-22 2016-08-08 Dow Agrosciences Llc Composiciones pesticidas sinergicas y metodos relacionados.
RU2667777C2 (ru) 2013-10-22 2018-09-24 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Пестицидные композиции и связанные с ними способы
NZ719688A (en) 2013-10-22 2017-06-30 Dow Agrosciences Llc Pesticidal compositions and related methods
AR098093A1 (es) 2013-10-22 2016-05-04 Dow Agrosciences Llc Composiciones pesticidas sinérgicas y métodos relacionados
CA2926438A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
RU2016119530A (ru) 2013-10-22 2017-11-28 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Синергетические пестицидные композиции и относящиеся к ним способы
WO2015143653A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
CN106488908A (zh) 2014-07-31 2017-03-08 美国陶氏益农公司 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法
CA2954631A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
WO2016018442A1 (en) 2014-07-31 2016-02-04 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3183238A4 (en) 2014-08-19 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
JP6538154B2 (ja) 2014-09-10 2019-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｅｔ（ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ）キナーゼ阻害剤としてのピリジン誘導体
AU2015316438B2 (en) 2014-09-10 2018-05-24 Glaxosmithkline Intellectual Property Development Limited Novel compounds as Rearranged during Transfection (RET) inhibitors
EP3191455A4 (en) 2014-09-12 2018-01-24 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
JP2017528486A (ja) 2014-09-17 2017-09-28 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物
GB201416513D0 (en) 2014-09-18 2014-11-05 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
HUE060104T2 (hu) 2015-02-27 2023-01-28 Verseon Int Corporation Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok
CA2978170C (en) 2015-03-09 2024-02-27 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
WO2016179558A1 (en) 2015-05-06 2016-11-10 The Regents Of The University Of California K-ras modulators
CN113773257A (zh) 2015-06-04 2021-12-10 奥瑞基尼探索技术有限公司 用作cdk抑制剂的经过取代的杂环衍生物
CA3032586A1 (en) * 2016-08-12 2018-02-15 Athenex, Inc. Biaryl compounds and use thereof for modulating a kinase cascade
CN110139853B (zh) 2016-12-29 2023-06-16 美国陶氏益农公司 用于制备杀有害生物化合物的方法
ES2922932T3 (es) * 2016-12-29 2022-09-21 Enyo Pharma Derivados de tiofeno como agentes antivirales
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
WO2018144620A1 (en) 2017-02-03 2018-08-09 Shire Human Genetic Therapies, Inc. Anti-fibrotic compounds
AU2018238138A1 (en) * 2017-03-21 2019-10-17 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
JP2020517600A (ja) 2017-04-20 2020-06-18 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｋ−Ｒａｓモジュレーター
AU2018380132B2 (en) 2017-12-06 2023-11-09 Lin Bioscience, Inc. Tubulin inhibitors
JP7184383B2 (ja) * 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
EP3774768A4 (en) * 2018-04-04 2022-01-05 Aurigene Discovery Technologies Limited SUBSTITUTED PYRAZOLE DERIVATIVES AS SELECTIVE CDK12 / 13 INHIBITORS
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
CN111793034B (zh) * 2020-07-24 2021-11-19 华中科技大学 苯并咪唑盐衍生物与制备抗肿瘤药物的应用
EP4229037A2 (en) * 2020-10-16 2023-08-23 CeMM - Forschungszentrum für Molekulare Medizin GmbH Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
TW202229268A (zh) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法
WO2023107714A2 (en) * 2021-12-10 2023-06-15 Prothena Biosciences Limited Methods for treating neurological disorders
WO2023203174A1 (en) * 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162360A (en) 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
CN1165482A (zh) 1994-11-10 1997-11-19 科西雷佩蒂斯公司 用作蛋白激酶抑制剂的吡唑药物组合物
AU5135998A (en) 1996-12-03 1998-06-29 Banyu Pharmaceutical Co., Ltd. Novel urea derivatives
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
CA2315720A1 (en) 1997-12-22 1999-07-01 Bayer Corporation Inhibition of p38 kinase activity using substituted heterocyclic ureas
UA67763C2 (ru) 1997-12-22 2004-07-15 Байер Фармасьютікалс Корпорейшн Translated By PlajСОЕДИНЕНИЕ И СПОСОБ ИНГИБИРОВАНИЯ RAF КИНАЗЫ С ПРИМЕНЕНИЕМ АРИЛ И ГЕТЕРОАРИЛ ЗАМЕЩЕННЫХ ГЕТЕРОЦИКЛИЧЕСКИХ МОЧЕВИННЫХ СОЕДИНЕНИЙ
ATE305782T1 (de) * 1999-08-12 2005-10-15 Pharmacia Italia Spa 3(5)-amino-pyrazolderivate, deren herstellungsverfahren und verwendung als krebshemmende mittel
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents

Also Published As

Publication number Publication date
BR0013143A (pt) 2002-06-11
AU4971400A (en) 2001-03-13
HK1046866A1 (zh) 2003-01-30
WO2001012189A1 (en) 2001-02-22
ATE305782T1 (de) 2005-10-15
US6218418B1 (en) 2001-04-17
ZA200201511B (en) 2003-05-28
HRP20020128A2 (en) 2003-04-30
NO20020684L (no) 2002-04-03
EP1202733B1 (en) 2005-10-05
PE20010130A1 (es) 2001-02-01
WO2001012189A8 (en) 2001-08-02
NZ517237A (en) 2004-02-27
DE60023012T2 (de) 2006-07-20
EE200200065A (et) 2003-04-15
AR026122A1 (es) 2003-01-29
PL353455A1 (en) 2003-11-17
DK1202733T3 (da) 2005-10-31
IS6265A (is) 2002-02-11
GEP20053476B (en) 2005-03-25
HUP0203542A3 (en) 2003-07-28
SK1812002A3 (en) 2003-02-04
JP2003507329A (ja) 2003-02-25
CA2383555A1 (en) 2001-02-22
EP1202733A4 (en) 2003-05-14
OA12046A (en) 2006-05-02
KR20020060160A (ko) 2002-07-16
IL147923A0 (en) 2002-08-14
BG106480A (en) 2002-09-30
MA25493A1 (fr) 2002-07-01
EA005373B1 (ru) 2005-02-24
CZ2002422A3 (cs) 2002-11-13
US7034049B1 (en) 2006-04-25
YU9602A (sh) 2004-11-25
HUP0203542A2 (en) 2003-05-28
EP1202733A1 (en) 2002-05-08
CN1373662A (zh) 2002-10-09
MXPA02001498A (es) 2003-07-21
NO20020684D0 (no) 2002-02-11
DE60023012D1 (de) 2006-02-16
AP2002002442A0 (en) 2002-03-31
ES2249270T3 (es) 2006-04-01
CA2383555C (en) 2009-02-17

Similar Documents

Publication Publication Date Title
EA200200248A1 (ru) Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
EA200200247A1 (ru) Производные арилметилкарбониламинотиазола и их применение в качестве противоопухолевых средств
EA200100230A1 (ru) Производные 1h-имидазопиридина
EA200201244A1 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
NO178764C (no) Fremgangsmåte ved fremstilling av oksetanoner
EA200100135A1 (ru) Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
HUP9701048A2 (hu) Új eljárás sildenafil előállítására és a felhasznált új köztitermékek
AU692090B2 (en) Novel 4,6-diarylpyrimidine derivatives and salts thereof
EA200500472A1 (ru) Ацетил 2-гидрокси-1,3-диаминоалканы
AU747521C (en) Cycloalkene derivatives, process for producing the same, and use
EA200500006A1 (ru) Лекарственное средство для лечения нейродегенеративных заболеваний
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
EA200000847A1 (ru) Противоопухолевые средства
EA200300804A1 (ru) Усовершенствованный способ получения карбапенема
SE8107273L (sv) 2-oxoazetidinderivat, sett att framstella democh anvendning derav
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
ES8301220A1 (es) Procedimiento para la preparacion de derivados de imidazol
GR3030034T3 (en) Tricyclic derivatives, pharmaceutical compositions containing them
DK0717042T3 (da) Fremgangsmåde til fremstilling af 1-(4,5-dihydro-2-thiazolyl)-3-azetidin-thiol-derivater
EA199900156A1 (ru) Новые производные эритромицина, способ их получения и их применение в качестве медикаментов
MX2023000382A (es) Inmunomoduladores heterocíclicos.
AU539177B2 (en) Amino alkoxy pyrazoles
EA200200292A1 (ru) Производные гигромицина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU